Physician in the Loop: Dermatology https://physicianintheloop.org/specialties/dermatology/ Transistor (https://transistor.fm) https://feeds.transistor.fm/physician-in-the-loop-dermatology The week's innovation news in dermatology for dermatologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/dermatology/. Read by AI voices. Nomad Medical Group, PLLC bd2e0b57-05ae-5fe3-9faf-d37e84e68fba yes en Sun, 08 Nov 2026 04:34:31 -0700 Sun, 08 Nov 2026 04:35:03 -0700 https://img.transistorcdn.com/CfOXh-sg54Fwm2CQ4GJ4uMQwzIrdOT-ggFhbD0-9CTs/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85OGY5/ZTg2NjRlNDc4OTVj/MzI3ZGY2MjYzZDNi/ODIzNi5qcGc.jpg Physician in the Loop: Dermatology https://physicianintheloop.org/specialties/dermatology/ episodic Nomad Medical The week's innovation news in dermatology for dermatologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/dermatology/. Read by AI voices. The week's innovation news in dermatology for dermatologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. dermatology, dermatology news, innovation, medicine, physicians, AI in medicine, weekly briefing Ryan Gillum No No Weekly Briefing for November 1 to 7, 2026 4 4 Weekly Briefing for November 1 to 7, 2026 full c6360158-72a1-4368-ac5f-7c8cf177e6fc https://share.transistor.fm/s/e9930c83 The American Academy of Dermatology Association (AADA) said on Nov. 5 that the final 2027 Medicare physician fee schedule will result in the largest cut ever imposed on skin cancer care. InventisBio reported topline phase 3 psoriasis results for the TYK2 inhibitor nomelcitinib. Johnson & Johnson reported phase 3 psoriatic arthritis results for oral icotrokinra.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The American Academy of Dermatology Association (AADA) said on Nov. 5 that the final 2027 Medicare physician fee schedule will result in the largest cut ever imposed on skin cancer care. InventisBio reported topline phase 3 psoriasis results for the TYK2 inhibitor nomelcitinib. Johnson & Johnson reported phase 3 psoriatic arthritis results for oral icotrokinra.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-11-01/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 08 Nov 2026 04:34:31 -0700 Nomad Medical Nomad Medical 162 AADA says final 2027 Medicare rule cuts dermatology pay about 6%; TYK2 inhibitor nomelcitinib meets phase 3 psoriasis goals AADA says final 2027 Medicare rule cuts dermatology pay about 6%; TYK2 inhibitor nomelcitinib meets phase 3 psoriasis goals Dermatology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 25 to 31, 2026 3 3 Weekly Briefing for October 25 to 31, 2026 full e83ebaa7-a501-4957-9642-9516e208a64c https://share.transistor.fm/s/8583e110 The Food and Drug Administration (FDA) approved Sun Pharma's tildrakizumab (Ilumya) for adults with active psoriatic arthritis, the company said Oct. 30. Oruka Therapeutics reported that its half-life extended IL-23p19 antibody ORKA-001 achieved complete skin clearance in 61% of high-dose patients in a phase 2b psoriasis trial.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> The Food and Drug Administration (FDA) approved Sun Pharma's tildrakizumab (Ilumya) for adults with active psoriatic arthritis, the company said Oct. 30. Oruka Therapeutics reported that its half-life extended IL-23p19 antibody ORKA-001 achieved complete skin clearance in 61% of high-dose patients in a phase 2b psoriasis trial.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-10-25/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 01 Nov 2026 04:04:00 -0700 Nomad Medical Nomad Medical 139 FDA approves tildrakizumab for psoriatic arthritis; half-life extended IL-23 antibody clears skin in 61% in phase 2b FDA approves tildrakizumab for psoriatic arthritis; half-life extended IL-23 antibody clears skin in 61% in phase 2b Dermatology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for October 11 to 17, 2026 2 2 Weekly Briefing for October 11 to 17, 2026 full c729861b-2682-48c9-b6d5-abb5bec2faab https://share.transistor.fm/s/3ae952b5 SciBase said Oct. 14 that Highmark Blue Cross Blue Shield issued the first positive U.S. medical policy for its Nevisense AI and impedance platform, for dermatologists evaluating atypical pigmented lesions.

A Lancet Rheumatology cohort study also tested spatial frequency domain imaging as a measure of skin fibrosis in systemic sclerosis.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> SciBase said Oct. 14 that Highmark Blue Cross Blue Shield issued the first positive U.S. medical policy for its Nevisense AI and impedance platform, for dermatologists evaluating atypical pigmented lesions.

A Lancet Rheumatology cohort study also tested spatial frequency domain imaging as a measure of skin fibrosis in systemic sclerosis.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-10-11/

Get this roundup by email, free

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Sun, 18 Oct 2026 09:05:59 -0600 Nomad Medical Nomad Medical 124 Highmark issues first U.S. payer policy covering Nevisense lesion testing; optical imaging tracks skin fibrosis in systemic sclerosis Highmark issues first U.S. payer policy covering Nevisense lesion testing; optical imaging tracks skin fibrosis in systemic sclerosis Dermatology,physicians,innovation,AI in medicine,weekly briefing No Weekly Briefing for September 28 to October 4, 2026 1 1 Weekly Briefing for September 28 to October 4, 2026 full 83dcbd29-a274-4020-a1c1-76e434a6abff https://share.transistor.fm/s/2a684ef2 Takeda said Sept. 30 that its oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib achieved complete skin clearance in 36.5% of patients with plaque psoriasis versus 13.9% with deucravacitinib in a head-to-head phase 3 trial.

The results were presented at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, where other data included phase 3b lebrikizumab results in hand and foot atopic dermatitis, three-year nemolizumab outcomes and a study linking GLP-1 receptor agonists to nail detachment.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Takeda said Sept. 30 that its oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib achieved complete skin clearance in 36.5% of patients with plaque psoriasis versus 13.9% with deucravacitinib in a head-to-head phase 3 trial.

The results were presented at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, where other data included phase 3b lebrikizumab results in hand and foot atopic dermatitis, three-year nemolizumab outcomes and a study linking GLP-1 receptor agonists to nail detachment.

Read this week's roundup and its sources: https://physicianintheloop.org/specialties/dermatology/2026-09-28/

The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

]]> Mon, 05 Oct 2026 22:02:01 -0600 Nomad Medical Nomad Medical 220 Zasocitinib beats deucravacitinib in head-to-head psoriasis trial; lebrikizumab improves hand and foot eczema; GLP-1 users report nail detachment Zasocitinib beats deucravacitinib in head-to-head psoriasis trial; lebrikizumab improves hand and foot eczema; GLP-1 users report nail detachment Dermatology,physicians,medical news,weekly briefing No